<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948766</url>
  </required_header>
  <id_info>
    <org_study_id>CENA713DUS44</org_study_id>
    <nct_id>NCT00948766</nct_id>
    <nct_alias>NCT01054755</nct_alias>
  </id_info>
  <brief_title>Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44</brief_title>
  <acronym>ACTION</acronym>
  <official_title>A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h
      transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h
      transdermally (5 cm^2 patch) in patients with Severe Dementia of the Alzheimer's Type in a
      24-week study. The extension study obtained additional safety and efficacy data, as well as
      provided the higher dose rivastigmine patch to all patients who completed the core study for
      an additional 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
    <description>The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a &quot;yes&quot; or &quot;no&quot; question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of &quot;yes&quot; reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
    <description>The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
    <description>The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician's rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient's treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient's available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Change From Baseline in the Neuropsychiatric Inventory (NPI-12) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
    <description>The NPI-12 assesses a wide range of behaviors encountered in patients with dementia to provide a means of distinguishing the frequency and severity of behavioral changes over time. Ten behavioral and 2 neurovegetative domains were evaluated in an interview with the caregiver given by a mental health professional. The scale included both frequency and severity ratings of each domain as well as a composite domain score (frequency x severity). The sum of the composite scores for the 12 domains yielded the NPI-12 total score. The NPI-12 was scored from 0 to 144, with lower scores reflecting improvement in psychiatric behavior. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the extension study</time_frame>
    <description>The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a &quot;yes&quot; or &quot;no&quot; question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of &quot;yes&quot; reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the extension study</time_frame>
    <description>The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24</measure>
    <time_frame>Baseline of the core study to Week 24 of the extension study</time_frame>
    <description>The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician's rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient's treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient's available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">716</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Rivastigmine 13.3 mg/24 h transdermal patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivastigmine 4.6 mg/24 h transdermal patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine 4.6 mg/24 h (5 cm^2)</intervention_name>
    <description>Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.</description>
    <arm_group_label>Rivastigmine 13.3 mg/24 h transdermal patch</arm_group_label>
    <arm_group_label>Rivastigmine 4.6 mg/24 h transdermal patch</arm_group_label>
    <other_name>ENA713D</other_name>
    <other_name>Exelon</other_name>
    <other_name>Exelon patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine 9.5 mg/24 h (10 cm^2)</intervention_name>
    <description>Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.</description>
    <arm_group_label>Rivastigmine 13.3 mg/24 h transdermal patch</arm_group_label>
    <other_name>ENA713D</other_name>
    <other_name>Exelon</other_name>
    <other_name>Exelon path</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine 13.3 mg/24 h (15 cm^2)</intervention_name>
    <description>Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.</description>
    <arm_group_label>Rivastigmine 13.3 mg/24 h transdermal patch</arm_group_label>
    <other_name>ENA713D</other_name>
    <other_name>Exelon</other_name>
    <other_name>Exelon patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.</description>
    <arm_group_label>Rivastigmine 13.3 mg/24 h transdermal patch</arm_group_label>
    <arm_group_label>Rivastigmine 4.6 mg/24 h transdermal patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Core study

        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer's disease (AD) according to National Institute of
             Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders
             Association (NINCDS/ADRDA) criteria.

          -  A Mini-Mental State Examination (MMSE) score of ≥ 3 and ≤ 12.

          -  Be able to complete at least 1 item on the Severe Impairment Battery (SIB).

          -  Residing with someone in the community or in regular contact with the primary
             caregiver.

          -  Be ambulatory or ambulatory with aid.

        Exclusion Criteria:

          -  An advanced, severe, progressive, or unstable disease of any type that may interfere
             with efficacy and safety assessments or put the patient at special risk.

          -  Patients currently residing in a nursing home.

          -  Any current medical or neurological condition other than AD that could explain the
             patient's dementia.

          -  A current diagnosis of probable or possible vascular dementia.

          -  A current diagnosis of severe or unstable cardiovascular disease.

          -  A current diagnosis of bradycardia (&lt; 50 beats per minute [bpm]), sick-sinus syndrome,
             or conduction defects.

          -  Clinically significant urinary obstruction.

          -  History of malignancy of any organ system within the past 5 years unless patient is
             verified to be in stable condition with no active metastasis.

          -  Current diagnosis of an active skin lesion/disorder that would prevent the patient
             from using a transdermal patch every day.

          -  A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar
             to rivastigmine, or to other cholinergic compounds.

          -  Taken any of the following substances (at the time of the Baseline Visit [Visit 2]).

          -  Succinylcholine-type muscle relaxants during the previous 2 weeks.

          -  Lithium during the previous 2 weeks.

          -  An investigational drug during the previous 4 weeks.

          -  A drug or treatment known to cause major organ system toxicity during the previous 4
             weeks.

          -  Rivastigmine (oral or transdermal patch), donepezil, galantamine, other cholinesterase
             inhibitors (eg, tacrine, physostigmine, or pyridostigmine), or other approved
             treatments for Alzheimer's disease during the previous 2 weeks, with exception of
             stable treatment with memantine for at least 3 months before study entry (Visit 1).

          -  Centrally acting anticholinergic drugs including tricyclic and tetracyclic
             antidepressants during the previous 4 weeks.

          -  Selegiline unless taken at a stable dose during the previous 4 weeks.

          -  Peripheral anticholinergics not taken at a stable dose during the previous 4 weeks.

        Extension study

        Inclusion Criteria:

          -  Complete the double-blind phase (Week 24) of the core study.

          -  Provide, if mentally competent, a separate written informed consent prior to
             participation in the extension study. In addition, the patient's caregiver, will
             provide written informed consent prior to the patient's participation in the
             open-label extension study. If the patient is not able to provide written informed
             consent, written informed consent must be obtained from the legally authorized
             representative on the patient's behalf.

          -  Continue to reside with someone in the community or in regular contact with the
             primary caregiver; patients who reside in an assisted living facility are eligible to
             participate.

          -  Continue to have a primary caregiver willing to accept responsibility for supervising
             treatment (eg, application and removal of the patch daily at approximately the same
             time of day), assessing the condition of the patient throughout the extension study.

          -  Must be medically stable and tolerating the current dose of rivastigmine patch as
             determined by the investigator.

        Exclusion Criteria:

        Refer to the core study protocol for full details of the exclusion criteria.

          -  Patients who discontinued the core study due to any reason are excluded.

          -  No additional exclusions may be applied by the investigator, in order to ensure that
             the study population will be representative of all eligible patients.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Neuro Specialist, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>86741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHS Research Center Inc.</name>
      <address>
        <city>Conway</city>
        <state>Arkansas</state>
        <zip>72034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Physicians Medical Group</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margolin Brain Institute</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCND Neuroscience Research Institute Inc./The Center for Memory and Aging</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Research Center</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Care of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Studies Dept. of Clinical Science and Medical Education</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Laboratories Memory Disorder Center</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research, Inc.</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologic Consultants, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White-Wilson Medical Center</name>
      <address>
        <city>Fort Walton Beach</city>
        <state>Florida</state>
        <zip>32547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Clinical Research, Inc</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Research, LLC</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies, Inc.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34285</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Neuroscience Institute</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic, LLC</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmerica Neuroscience Reseach Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Clinical Research Solutions</name>
      <address>
        <city>Manhattan</city>
        <state>Kansas</state>
        <zip>66502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center/Department of Psychiatry Psychopharmacology Research Clinic</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Gary Booker, MD APMC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Samuel and Alexia Bratton Memory Clinic, William Hill Inc</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research of the Berkshires</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Neurology Associates, P.C.</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Detroit Medical center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <zip>49442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orr &amp; Associates Memory and Geriatric Behavioral Health Clinic</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Clinic, Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neuroscience Center</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky, LLC.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Research Institute, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of America, Inc.</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research Corporation</name>
      <address>
        <city>Manchester</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroCognitive Institute</name>
      <address>
        <city>Mt. Arlington</city>
        <state>New Jersey</state>
        <zip>07856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ-Robert Wood Johnson Medical Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ-School of Osteopathic Medicine Center</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <zip>08084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research, LLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Care of Central NY</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastside Comprehensive medical Center, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan S. Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Medical Research of Staten Island</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burke Rehabilitation Hospital</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Memory Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Research</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Neurology, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Assessment Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Center for Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Clinical Research</name>
      <address>
        <city>Bridgeville</city>
        <state>Pennsylvania</state>
        <zip>15017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Veterans Affairs Medical Center</name>
      <address>
        <city>Coatesville</city>
        <state>Pennsylvania</state>
        <zip>19320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmoreland Neurology associates, Inc.</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <zip>15601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Protocol Management Specialists</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Consultants, PC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacinto Medical Group, PA</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grayline Clinical Drug Trials</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Neurology, P.L.L.C</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVA Neurology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Group, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Excellence in Aging and Geriatric Health</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Northwest</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Psychiatric Consultants, SC</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Medical Center</name>
      <address>
        <city>Bayamon</city>
        <zip>00959</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSPIRA Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AlzheimersDiseaseStudy.com</url>
    <description>Online Screening Questionnaire is available</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <results_first_submitted>January 8, 2013</results_first_submitted>
  <results_first_submitted_qc>January 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>dementia</keyword>
  <keyword>Alzheimer's type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient in each treatment group in the core study and one patient in the treatment group in the extension study did not receive study medication; they were not included in the safety set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
        </group>
        <group group_id="P2">
          <title>Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="360"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="359"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Effect</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="397">397 of the 463 patients who completed the core study entered the extension study.</participants>
                <participants group_id="P2" count="0">No patients received this treatment in the extension study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Effect</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Drug No Longer Required</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Core Study: Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
        </group>
        <group group_id="B2">
          <title>Core Study: Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="356"/>
            <count group_id="B2" value="360"/>
            <count group_id="B3" value="716"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.6" spread="8.69"/>
                    <measurement group_id="B2" value="76.5" spread="9.35"/>
                    <measurement group_id="B3" value="77.0" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Study: Change From Baseline in the Alzheimer’s Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24</title>
        <description>The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a &quot;yes&quot; or &quot;no&quot; question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of &quot;yes&quot; reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement.</description>
        <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
        <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline in the Alzheimer’s Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24</title>
          <description>The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a &quot;yes&quot; or &quot;no&quot; question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of &quot;yes&quot; reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement.</description>
          <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="6.82"/>
                    <measurement group_id="O2" value="-3.6" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24</title>
        <description>The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement.</description>
        <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
        <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24</title>
          <description>The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement.</description>
          <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="13.54"/>
                    <measurement group_id="O2" value="-6.4" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24</title>
        <description>The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician’s rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient’s treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient’s available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported.</description>
        <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
        <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24</title>
          <description>The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician’s rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient’s treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient’s available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported.</description>
          <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marked worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Change From Baseline in the Neuropsychiatric Inventory (NPI-12) Score at Week 24</title>
        <description>The NPI-12 assesses a wide range of behaviors encountered in patients with dementia to provide a means of distinguishing the frequency and severity of behavioral changes over time. Ten behavioral and 2 neurovegetative domains were evaluated in an interview with the caregiver given by a mental health professional. The scale included both frequency and severity ratings of each domain as well as a composite domain score (frequency x severity). The sum of the composite scores for the 12 domains yielded the NPI-12 total score. The NPI-12 was scored from 0 to 144, with lower scores reflecting improvement in psychiatric behavior. A negative change score indicates improvement.</description>
        <time_frame>Baseline of the core study to Week 24 of the core study</time_frame>
        <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline in the Neuropsychiatric Inventory (NPI-12) Score at Week 24</title>
          <description>The NPI-12 assesses a wide range of behaviors encountered in patients with dementia to provide a means of distinguishing the frequency and severity of behavioral changes over time. Ten behavioral and 2 neurovegetative domains were evaluated in an interview with the caregiver given by a mental health professional. The scale included both frequency and severity ratings of each domain as well as a composite domain score (frequency x severity). The sum of the composite scores for the 12 domains yielded the NPI-12 total score. The NPI-12 was scored from 0 to 144, with lower scores reflecting improvement in psychiatric behavior. A negative change score indicates improvement.</description>
          <population>Modified full analysis set: All randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline measurement of the co-primary efficacy variables. Only patients with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="14.01"/>
                    <measurement group_id="O2" value="1.2" spread="16.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24</title>
        <description>The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a &quot;yes&quot; or &quot;no&quot; question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of &quot;yes&quot; reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement.</description>
        <time_frame>Baseline of the core study to Week 24 of the extension study</time_frame>
        <population>Modified full analysis set: All patients who received at least 1 application of study medication and had at least 1 efficacy assessment in the extension study. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24</title>
          <description>The ADCS-ADL-SIV is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. For each of the 19 questions in the ADCS-ADL-SIV, there was either a forced choice of best response or a &quot;yes&quot; or &quot;no&quot; question with additional sub-questions. Responses for each item were obtained from the caregiver through an interview. Higher numbered scores and answers of &quot;yes&quot; reflected a more self-sufficient individual. The total score was calculated as the sum of all items and sub-questions and ranged from 0 to 54. A higher total score represented a higher functioning patient. A positive change score indicates improvement.</description>
          <population>Modified full analysis set: All patients who received at least 1 application of study medication and had at least 1 efficacy assessment in the extension study. Only patients with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24</title>
        <description>The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement.</description>
        <time_frame>Baseline of the core study to Week 24 of the extension study</time_frame>
        <population>Modified full analysis set: All patients who received at least 1 application of study medication and had at least 1 efficacy assessment in the extension study. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24</title>
          <description>The SIB is a 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced Alzheimer Disease patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuo-spatial ability, construction, and orienting to name. The items of the SIB were developed as simple 1-step commands which are presented by a trained rater with gestural cues and repeated if necessary. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. A positive change score indicates improvement.</description>
          <population>Modified full analysis set: All patients who received at least 1 application of study medication and had at least 1 efficacy assessment in the extension study. Only patients with available data were included in the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24</title>
        <description>The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician’s rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient’s treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient’s available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported.</description>
        <time_frame>Baseline of the core study to Week 24 of the extension study</time_frame>
        <population>Modified full analysis set: All patients who received at least 1 application of study medication and had at least 1 efficacy assessment in the extension study. Only patients with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
            <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24</title>
          <description>The ADCS-CGIC assesses the clinical meaningfulness of a treatment based on the clinician’s rating of change. The rating is provided by a trained clinician or psychometrician blinded to the patient’s treatment. The rater interviewed the patient and caregiver separately at Baseline using a worksheet that provided space for notes and comments. At baseline, raters had access to all of the patient’s available records and evaluations. The rater used a similar worksheet at follow-up visits, and referred to the baseline worksheet prior to making a rating of change. The worksheets were divided into 3 domains: mental/cognitive state, behavior, and functioning. Change ratings were based on a 7-point scale: Marked (1), moderate (2), and minimal improvement (3), no change (4), and marked (5), moderate (6), and minimal worsening (7). The percentage of patients in each of the 7 categories is reported.</description>
          <population>Modified full analysis set: All patients who received at least 1 application of study medication and had at least 1 efficacy assessment in the extension study. Only patients with available data were included in the analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marked worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from randomization in the core study through the end of the extension study (48 weeks).</time_frame>
      <desc>Safety set: All patients who received at least 1 dose of study medication and had at least 1 safety assessment after baseline. One patient in each treatment group did not receive study medication and were not included in the safety set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Core Study: Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
        </group>
        <group group_id="E2">
          <title>Core Study: Rivastigmine 4.6 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 4.6 mg/24 h (5 cm^2).</description>
        </group>
        <group group_id="E3">
          <title>Extension Study: Rivastigmine 13.3 mg/24 h Transdermal Patch</title>
          <description>Patients received rivastigmine 13.3 mg/24 h (15 cm^2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dysstasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Mutism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cystopexy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bloody discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="248" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

